Literature DB >> 30562606

Novel role of SF1 in alleviating thyroid-associated ophthalmopathy through the AMPK/mTOR signaling pathway.

Xiao-Xia Wang1, Xiao-Xiong Wang2, Xiao-Fan Jia1, Tan Guo3, Tong-Zhang Xian1, Li Liu1, Zhu-Jin Xu3, Yue Guo4, Xiang Deng5, Li-Na Zhang1, Fu-Li Man1, Xian-Bo Zhang1, Tong Chen2, Qi Pan6, Li-Xin Guo7.   

Abstract

BACKGROUND/AIM: Thyroid-associated ophthalmopathy (TAO) is a chronic autoimmune disorder characterized by an increased volume of adipose/connective tissue. This study aims to explore whether steroidogenic factor 1 (SF1) is implicated in development of TAO through the adenosine monophosphate-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) signaling pathway.
METHODS: Initially, we extracted orbital preadipocytes from 10 TAO patients for culture and identification. After differentiation, cells were inoculated with plasmids with overexpressed SF1, and plasmids with siRNA against SF1, respectively. Then fat content and PGE2 secretion were measured by using ELISA. The levels of SF1, Bax, Bcl-2, Caspase3, Pref-1, PPARγ, Leptin, Adiponectin, p-AMPKαThr172, p-mTORSer2448, and p-S6KThr389 were detected by RT-qPCR and western blot analysis. Cell proliferation and apoptosis were measured by EdU and flow cytometry.
RESULTS: TAO patients showed reduced SF1 expression in orbital preadipocytes. Overexpression of SF1 led to inhibited expression of Bcl-2, PPARγ, Leptin, Adiponectin and p-AMPKαThr172, fat content, cell proliferation and differentiation, but increased levels of Bax, Caspase3, Pref-1, p-mTORSer2448 and p-S6KThr389, PGE2 secretion and apoptosis rate.
CONCLUSION: Our result showed up-regulated SF1 may relieve TAO through suppressing cell proliferation and differentiation, but accelerating cell apoptosis by inhibiting the activation of the AMPK/mTOR signaling pathway.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AMPK/mTOR signaling pathway; Orbital preadipocyte; SF1; Thyroid-associated ophthalmopathy

Mesh:

Substances:

Year:  2018        PMID: 30562606     DOI: 10.1016/j.gene.2018.11.097

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  4 in total

Review 1.  New Therapeutic Horizon of Graves' Hyperthyroidism: Treatment Regimens Based on Immunology and Ingredients From Traditional Chinese Medicine.

Authors:  Qiongyao He; Hui Dong; Minmin Gong; Yujin Guo; Qingsong Xia; Jing Gong; Fuer Lu
Journal:  Front Pharmacol       Date:  2022-04-05       Impact factor: 5.988

2.  Mechanisms of Spica Prunellae against thyroid-associated Ophthalmopathy based on network pharmacology and molecular docking.

Authors:  Yuhan Zhang; Xianzhi Li; Congcong Guo; Jianjun Dong; Lin Liao
Journal:  BMC Complement Med Ther       Date:  2020-07-20

3.  Identification of tRNA-Related Fragments and Their Potential Regulatory Effects in Thyroid-Associated Ophthalmopathy.

Authors:  Zifan Yue; Fei Tong; Chengcheng Zeng; Ruili Wei
Journal:  Front Genet       Date:  2022-04-04       Impact factor: 4.772

4.  Comprehensive Analysis of lncRNA Expression Profile and the Potential Role of ENST00000604491 in Graves' Disease.

Authors:  Yingzhao Liu; Junli Zou; Juan Xu; Xuehua Wang; Jie Xing; Li Wang; Huiyong Peng
Journal:  J Immunol Res       Date:  2022-04-25       Impact factor: 4.493

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.